<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04278820</url>
  </required_header>
  <id_info>
    <org_study_id>TQA3526-Ⅱ-01</org_study_id>
    <nct_id>NCT04278820</nct_id>
  </id_info>
  <brief_title>A Study of TQA3526 in the Treatment of Primary Biliary Cirrhosis (PBC)</brief_title>
  <official_title>A Phase IIa, Randomized, Double-blind, Placebo-controlled Study of TQA3526 in the Treatment of Naive or Previously Treated PBC Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      TQA3526 is a modified bile acid and FXR agonist. FXR is a key regulator of bile acid
      synthesis and transport. Bile acids are used by the body to help with digestion. It is
      hypothesized that regular treatment with TQA3526 will improve liver function in persons with
      Primary Biliary Cirrhosis (PBC).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 20, 2020</start_date>
  <completion_date type="Anticipated">November 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Alkaline phosphatase (ALP)</measure>
    <time_frame>Baseline up to 24w</time_frame>
    <description>The reduction of ALP level from baseline to 24 weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Liver function：ALP (excluding 12W/24W), ALT, AST, GGT, TBA and Tbil</measure>
    <time_frame>Baseline up to 2, 4, 8, 12, 14, 16, 20, 24 weeks</time_frame>
    <description>The reduction of ALP , ALT, AST, GGT, TBA and Tbil from baseline to each time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting lipid：LDL-C、HDL-C、TG and TC</measure>
    <time_frame>Baseline up to 2, 4, 8, 12, 14, 16, 20, 24 weeks</time_frame>
    <description>The rate of change of LDL-C、HDL-C、TG and TC from baseline to each time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>predose, Weeks 2, 4, 8, 12, 14, 16, 20, 24 : 0, 1.5, 3.5 hours following drug administration</time_frame>
    <description>Maximum concentration of the analyte in plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax</measure>
    <time_frame>predose, Weeks 2, 4, 8, 12, 14, 16, 20, 24 : 0, 1.5, 3.5 hours following drug administration</time_frame>
    <description>Time from dosing to maximum concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-∞</measure>
    <time_frame>predose, Weeks 2, 4, 8, 12, 14, 16, 20, 24 : 0, 1.5, 3.5 hours following drug administration</time_frame>
    <description>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pharmacodynamics</measure>
    <time_frame>Baseline up to 2, 4, 8, 12, 14, 16, 20, 24 weeks</time_frame>
    <description>The rate of change of FGF-19、C4、IgG and IgM from baseline to each time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety and tolerability: incidence of treatment emergent adverse events and serious treatment emergent adverse events</measure>
    <time_frame>Baseline up to 2, 4, 8, 12, 14, 16, 20, 24 weeks</time_frame>
    <description>Evaluate safety and tolerability as assessed by the incidence of treatment emergent adverse events and serious treatment emergent adverse events comparing TQA3526 to placebo.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Primary Biliary Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Climbing group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Titration group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Extension group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TQA3526</intervention_name>
    <description>Tablet(s) administered orally once daily</description>
    <arm_group_label>Climbing group</arm_group_label>
    <arm_group_label>Extension group</arm_group_label>
    <arm_group_label>Titration group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to match TQA3526</intervention_name>
    <description>Tablet(s) administered orally once daily</description>
    <arm_group_label>Climbing group</arm_group_label>
    <arm_group_label>Extension group</arm_group_label>
    <arm_group_label>Titration group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1.18 and 70 years old, male or female. 2.Proven as PBC, as demonstrated by the patient
             presenting with at least 2 of the following 3 diagnostic factors:

               -  History of increased ALP levels for at least 3 months prior to Day 0 in
                  previously treated PBC patients，or ALP levels increased during screening in
                  treatment naive PBC patients； ② Positive AMA titer (&gt;1:40 titer on
                  immunofluorescence or M2 positive by ELISA) or PBC-specific antinuclear
                  antibodies (anti-GP210 and anti-SP100 positive)； ③ Liver biopsy consistent with
                  PBC within 24W prior to randomization； 3.ALP value between 1.67 and 10 × ULN;
                  4.Taking ursodeoxycholic acid (UDCA) for at least 12 months (stable dose for ≥ 3
                  months) prior to Day 0, or unable to tolerate UDCA (no UDCA for ≥ 3 months) prior
                  to Day 0.

        Exclusion Criteria:

          -  1.Has other virus infected ; 2.History or presence of other concomitant liver
             diseases； 3.Presence of clinical complications of PBC or clinically significant
             hepatic decompensation； 4.Child-pugh grade B or C in patients with cirrhosis；
             5.Creatinine (Cr) ≥1.5 times the upper limit of normal value and serum creatinine
             clearance rate &lt;60mL/min； 6.ALT or AST&gt;5×ULN；TBil&gt;3×ULN； 7.Patients with a history of
             severe pruritus within 2 months prior to day 0; 8.History or presence of clinically
             concerning cardiac arrhythmias, the duration of the study may affect survival;
             9.Presence of any other disease or condition that is interfering with the absorption,
             distribution, metabolism, or excretion of drugs including bile salt metabolism in the
             intestine; 10.Medical conditions that may cause nonhepatic increases in ALP (e.g.,
             Paget's disease) or which may diminish life expectancy to &lt; 2 years.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Junqi Niu</last_name>
    <phone>13756661205</phone>
    <email>junqiniu@aliyun.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The first hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Junqi Niu</last_name>
      <phone>13756661205</phone>
      <email>junqiniu@aliyun.com</email>
    </contact>
    <investigator>
      <last_name>Junqi Niu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>January 18, 2020</study_first_submitted>
  <study_first_submitted_qc>February 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 20, 2020</study_first_posted>
  <last_update_submitted>February 18, 2020</last_update_submitted>
  <last_update_submitted_qc>February 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Liver Cirrhosis, Biliary</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

